Inhibition/NN
of/IN
cyclooxygenase-2/NN
expression/NN
by/IN
4-trifluoromethyl/NN
derivatives/NNS
of/IN
salicylate/NN
,/,
triflusal/NN
,/,
and/CC
its/PRP$
deacetylated/VBN
metabolite/NN
,/,
2-hydroxy-4-trifluoromethylbenzoic/JJ
acid/NN
./.

The/DT
therapeutic/JJ
potential/NN
of/IN
drugs/NNS
that/WDT
block/VBP
the/DT
induction/NN
of/IN
cyclooxygenase-2/NN
has/VBZ
been/VBN
emphasized/VBN
./.
=====
When/WRB
two/CD
4-trifluoromethyl/NN
salicylate/NN
derivatives/NNS
[/(
2-acetoxy-4-trifluoromethyl-benzoic/JJ
acid/NN
(/(
triflusal/NN
)/)
and/CC
its/PRP$
deacetylated/VBN
metabolite/NN
2-hydroxy-4-trifluoromethylbenzoic/JJ
acid/NN
(/(
HTB/NN
)/)
]/)
were/VBD
compared/VBN
with/IN
aspirin/NN
and/CC
sodium/NN
salicylate/NN
as/IN
cyclooxygenase-2/NN
(/(
COX-2/NN
)/)
inhibitors/NNS
,/,
we/PRP
observed/VBD
that/IN
in/IN
bacterial/JJ
lipopolysaccharide-activated/JJ
human/JJ
blood/NN
,/,
triflusal/NN
,/,
aspirin/NN
,/,
and/CC
HTB/NN
,/,
but/CC
not/RB
sodium/NN
salicylate/NN
,/,
inhibited/VBD
COX-2-mediated/JJ
prostaglandin/NN
E2/NN
(/(
PGE2/NN
)/)
production/NN
(/(
IC50/NN
=/JJ
0.16/CD
,/,
0.18/CD
,/,
0.39/CD
,/,
and/CC
>/JJR
10/CD
mM/NN
,/,
respectively/RB
)/)
./.
=====
However/RB
,/,
only/RB
triflusal/NN
and/CC
aspirin/NN
inhibited/VBD
purified/VBN
COX-2/NN
enzyme/NN
./.
=====
To/TO
test/VB
this/DT
apparent/JJ
discrepancy/NN
,/,
we/PRP
realized/VBD
that/IN
HTB/NN
and/CC
triflusal/NN
(/(
but/CC
neither/CC
aspirin/NN
nor/CC
salicylate/NN
)/)
produced/VBD
a/DT
concentration-dependent/JJ
inhibition/NN
of/IN
COX-2/NN
protein/NN
expression/NN
in/IN
peripheral/JJ
human/JJ
mononuclear/JJ
cells/NNS
./.
=====
This/DT
observation/NN
was/VBD
further/RB
confirmed/VBN
in/IN
a/DT
rat/NN
air/NN
pouch/NN
model/NN
in/FW
vivo/FW
,/,
in/IN
which/WDT
both/CC
aspirin/NN
and/CC
triflusal/NN
inhibited/VBD
PGE2/NN
production/NN
(/(
ID50/NN
=/JJ
18.9/CD
and/CC
11.4/CD
mg/kg/NN
p.o./NN
,/,
respectively/RB
)/)
but/CC
only/RB
triflusal-treated/JJ
animals/NNS
showed/VBD
a/DT
decrease/NN
in/IN
COX-2/NN
expression/NN
./.
=====
This/DT
different/JJ
behavior/NN
may/MD
be/VB
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
due/JJ
to/TO
the/DT
ability/NN
of/IN
HTB/NN
and/CC
triflusal/NN
to/TO
block/VB
the/DT
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
nuclear/JJ
factor-kappaB/NN
to/TO
a/DT
higher/JJR
extent/NN
than/IN
aspirin/NN
and/CC
sodium/NN
salicylate/NN
./.
=====
Thus/RB
,/,
in/IN
addition/NN
to/TO
inhibiting/VBG
the/DT
COX-2/NN
activity/NN
at/IN
therapeutic/JJ
concentrations/NNS
,/,
triflusal/NN
is/VBZ
able/JJ
to/TO
block/VB
through/IN
its/PRP$
metabolite/NN
HTB/NN
the/DT
expression/NN
of/IN
new/JJ
enzyme/NN
,/,
and/CC
hence/RB
the/DT
resumption/NN
of/IN
PGE2/NN
synthesis/NN
./.
=====
Triflusal/NN
and/CC
HTB/NN
may/MD
exert/VB
beneficial/JJ
effects/NNS
in/IN
processes/NNS
in/IN
which/WDT
de/FW
novo/FW
COX-2/NN
expression/NN
is/VBZ
involved/VBN
and/CC
,/,
in/IN
a/DT
broader/JJR
sense/NN
,/,
in/IN
pathological/JJ
situations/NNS
in/IN
which/WDT
genes/NNS
under/IN
nuclear/JJ
factor-kappaB/NN
control/NN
are/VBP
up-regulated/VBN
./.